Co-Authors
This is a "connection" page, showing publications co-authored by Po-Ren Hsueh and Wen-Chien Ko.
Connection Strength
6.936
-
Arguments in favour of remdesivir for treating SARS-CoV-2 infections. Int J Antimicrob Agents. 2020 04; 55(4):105933.
Score: 0.870
-
National surveillance of antimicrobial susceptibilities to dalbavancin, telavancin, tedizolid, eravacycline, omadacycline and other comparator antibiotics and serotype distribution of invasive Streptococcus pneumoniae isolates in adults: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) programme in 2017-2020. J Glob Antimicrob Resist. 2021 09; 26:308-316.
Score: 0.239
-
COVID-19 vaccines and thrombosis with thrombocytopenia syndrome. Expert Rev Vaccines. 2021 08; 20(8):1027-1035.
Score: 0.239
-
COVID-19 vaccines: concerns beyond protective efficacy and safety. Expert Rev Vaccines. 2021 08; 20(8):1013-1025.
Score: 0.239
-
Increased antimicrobial resistance during the COVID-19 pandemic. Int J Antimicrob Agents. 2021 Apr; 57(4):106324.
Score: 0.234
-
The impact of the coronavirus disease 2019 epidemic on notifiable infectious diseases in Taiwan: A database analysis. Travel Med Infect Dis. 2021 Mar-Apr; 40:101997.
Score: 0.233
-
The impact of COVID-19 preventative measures on airborne/droplet-transmitted infectious diseases in Taiwan. J Infect. 2021 03; 82(3):e30-e31.
Score: 0.229
-
A Review of Treatment of Coronavirus Disease 2019 (COVID-19): Therapeutic Repurposing and Unmet Clinical Needs. Front Pharmacol. 2020; 11:584956.
Score: 0.228
-
In vitro diagnostics of coronavirus disease 2019: Technologies and application. J Microbiol Immunol Infect. 2021 Apr; 54(2):164-174.
Score: 0.221
-
Extra-respiratory manifestations of COVID-19. Int J Antimicrob Agents. 2020 Aug; 56(2):106024.
Score: 0.221
-
SARS-CoV-2 and COVID-19. J Microbiol Immunol Infect. 2020 Jun; 53(3):363-364.
Score: 0.219
-
Global epidemiology of coronavirus disease 2019 (COVID-19): disease incidence, daily cumulative index, mortality, and their association with country healthcare resources and economic status. Int J Antimicrob Agents. 2020 Apr; 55(4):105946.
Score: 0.218
-
A case of COVID-19 and pneumonia returning from Macau in Taiwan: Clinical course and anti-SARS-CoV-2 IgG dynamic. J Microbiol Immunol Infect. 2020 Jun; 53(3):485-487.
Score: 0.218
-
Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths. J Microbiol Immunol Infect. 2020 Jun; 53(3):404-412.
Score: 0.218
-
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020 Mar; 55(3):105924.
Score: 0.217
-
Prevalence and risk factors for colonization by extended-spectrum ß-lactamase-producing or ST 131 Escherichia coli among asymptomatic adults in community settings in Southern Taiwan. Infect Drug Resist. 2019; 12:1063-1071.
Score: 0.205
-
Susceptibility rates of clinically important bacteria collected from intensive care units against colistin, carbapenems, and other comparative agents: results from Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART). Infect Drug Resist. 2019; 12:627-640.
Score: 0.203
-
Antimicrobial activities of ceftazidime-avibactam, ceftolozane-tazobactam, and other agents against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa isolated from intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan in 2016. Infect Drug Resist. 2019; 12:545-552.
Score: 0.203
-
Carbapenem-Resistant Enterobacteriaceae Infections: Taiwan Aspects. Front Microbiol. 2018; 9:2888.
Score: 0.199
-
In vitro activity of ceftazidime-avibactam, ceftolozane-tazobactam, and other comparable agents against clinically important Gram-negative bacilli: results from the 2017 Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART). Infect Drug Resist. 2018; 11:1983-1992.
Score: 0.198
-
Nationwide surveillance of ribotypes and antimicrobial susceptibilities of toxigenic Clostridium difficile isolates with an emphasis on reduced doxycycline and tigecycline susceptibilities among ribotype 078 lineage isolates in Taiwan. Infect Drug Resist. 2018; 11:1197-1203.
Score: 0.195
-
QuantiFERON-TB Gold Plus Is a More Sensitive Screening Tool than QuantiFERON-TB Gold In-Tube for Latent Tuberculosis Infection among Older Adults in Long-Term Care Facilities. J Clin Microbiol. 2018 08; 56(8).
Score: 0.195
-
Methicillin-resistant Staphylococcus aureus sequence type 45 with high rates of ciprofloxacin and tetracycline resistance in the residents and environments of long-term care facilities in Taiwan. J Infect. 2018 03; 76(3):305-307.
Score: 0.186
-
Role of rifampin for the treatment of bacterial infections other than mycobacteriosis. J Infect. 2017 11; 75(5):395-408.
Score: 0.183
-
Clinical manifestations of candidemia caused by uncommon Candida species and antifungal susceptibility of the isolates in a regional hospital in Taiwan, 2007-2014. J Microbiol Immunol Infect. 2019 Aug; 52(4):612-619.
Score: 0.183
-
Corrigendum to "Rates of susceptibility of carbapenems, ceftobiprole, and colistin against clinically important bacteria collected from intensive care units in 2007: Results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART)" [J Microbiol Immunol Infect 49 (2016) 969-976]. J Microbiol Immunol Infect. 2018 Jun; 51(3):423-424.
Score: 0.177
-
Presence of multidrug-resistant organisms in the residents and environments of long-term care facilities in Taiwan. J Microbiol Immunol Infect. 2017 Apr; 50(2):133-144.
Score: 0.176
-
Epidemiology and antimicrobial susceptibility profiles of Gram-negative bacteria causing urinary tract infections in the Asia-Pacific region: 2009-2010 results from the Study for Monitoring Antimicrobial Resistance Trends (SMART). Int J Antimicrob Agents. 2012 Jun; 40 Suppl:S37-43.
Score: 0.127
-
Multicenter evaluation of two chemiluminescence and three lateral flow immunoassays for the diagnosis of COVID-19 and assessment of antibody dynamic responses to SARS-CoV-2 in Taiwan. Emerg Microbes Infect. 2020 Dec; 9(1):2157-2168.
Score: 0.057
-
COVID-19 in long-term care facilities: An upcoming threat that cannot be ignored. J Microbiol Immunol Infect. 2020 Jun; 53(3):444-446.
Score: 0.055
-
Implementation of a national quality improvement program to enhance hand hygiene in nursing homes in Taiwan. J Microbiol Immunol Infect. 2019 Apr; 52(2):345-351.
Score: 0.049
-
Clinical characteristics of patients with bacteraemia due to the emergence of mcr-1-harbouring Enterobacteriaceae in humans and pigs in Taiwan. Int J Antimicrob Agents. 2018 Nov; 52(5):651-657.
Score: 0.049
-
Predominance of methicillin-resistant Staphylococcus aureus in the residents and environments of long-term care facilities in Taiwan. J Microbiol Immunol Infect. 2019 Feb; 52(1):62-74.
Score: 0.047
-
National bundle care program implementation to reduce ventilator-associated pneumonia in intensive care units in Taiwan. J Microbiol Immunol Infect. 2019 Aug; 52(4):592-597.
Score: 0.047
-
Are we ready for the global emergence of multidrug-resistant Candida auris in Taiwan? J Formos Med Assoc. 2018 Jun; 117(6):462-470.
Score: 0.046
-
Implementation of a national bundle care program to reduce central line-associated bloodstream infections in intensive care units in Taiwan. J Microbiol Immunol Infect. 2018 Oct; 51(5):666-671.
Score: 0.046
-
Implementation of a national bundle care program to reduce catheter-associated urinary tract infection in high-risk units of hospitals in Taiwan. J Microbiol Immunol Infect. 2017 Aug; 50(4):464-470.
Score: 0.045
-
Characterization of acquired beta-lactamases and their genetic support in multidrug-resistant Pseudomonas aeruginosa isolates in Taiwan: the prevalence of unusual integrons. J Antimicrob Chemother. 2006 Sep; 58(3):530-6.
Score: 0.021